CABALETTA BIO, INC. Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration
CABALETTA BIO, INC. (CABA) had Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration of $319.64 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Alternative
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration · last filed 2026-03-23
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration $319.64M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration $157.20M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration $121.32M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration $98.92M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration |
|---|---|
| 2025-12-31 | $319.64M 10-K · filed 2026-03-23 |
| 2024-12-31 | $157.20M 10-K · filed 2025-03-31 |
| 2023-12-31 | $121.32M 10-K · filed 2024-03-21 |
| 2022-12-31 | $98.92M 10-K · filed 2023-03-16 |
| 2021-12-31 | $85.55M 10-K · filed 2022-03-17 |
| 2020-12-31 | $45.30M 10-K · filed 2021-03-16 |
| 2019-12-31 | $17.23M 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |